Where does CBLI stock trade?

Cleveland BioLabs, Inc. (CBLI) is listed on NASDAQ.

What sector and industry is CBLI in?

Cleveland BioLabs, Inc. operates in the Health Care sector, Biotechnology: Commercial Physical & Biological Resarch industry.

When did Cleveland BioLabs, Inc. go public?

Cleveland BioLabs, Inc. (CBLI) completed its IPO in 2006.

What companies are similar to CBLI?

Notable peers in the same industry include IQV (IQVIA Holdings Inc.), INCY (Incyte Corp.), PPD (PPD, Inc.), MEDP (Medpace Holdings Inc.), ICLR (ICON plc). Compare CBLI side-by-side with any of them on Quantisnow.

How can I track CBLI on Quantisnow?

Quantisnow aggregates Cleveland BioLabs, Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CBLI to receive live email and push alerts on every new disclosure.

CBLI

NASDAQ

Cleveland BioLabs, Inc.

SectorHealth CareIndustryBiotechnology: Commercial Physical & Biological ResarchIPO2006

News25/Ratings0

Latest news

25 items

1693dINSIDER
SEC Form 4: Barbarick Steve K was granted 60,000 shares
4 - Statera Biopharma, Inc. (0001318641) (Issuer)
1693dINSIDER
SEC Form 4: Verny Lea was granted 60,000 shares
4 - Statera Biopharma, Inc. (0001318641) (Issuer)
1700dSEC
SEC Form DEF 14A filed by Cleveland BioLabs, Inc.
DEF 14A - Statera Biopharma, Inc. (0001318641) (Filer)
1712dINSIDER
SEC Form 4: Markvicka Taunia was granted 100,000 shares
4 - Statera Biopharma, Inc. (0001318641) (Issuer)
1713dSEC
Cleveland BioLabs, Inc. filed SEC Form 8-K: Changes in Registrant’s Certifying Accountant, Financial Statements and Exhibits
8-K - Statera Biopharma, Inc. (0001318641) (Filer)
1714dSEC
Cleveland BioLabs, Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
8-K - Statera Biopharma, Inc. (0001318641) (Filer)
1732dSEC
SEC Form 424B5 filed by Cleveland BioLabs, Inc.
424B5 - Statera Biopharma, Inc. (0001318641) (Filer)
1741dSEC
Cleveland BioLabs, Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
8-K - Statera Biopharma, Inc. (0001318641) (Filer)
1742dPR
Cytocom, Inc. Announces Plan to Adopt New Corporate Name "Statera BioPharma, Inc."
FORT COLLINS, Colo., Aug. 31, 2021 /PRNewswire/ -- Cytocom, Inc. (NASDAQ:CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced plans to change its corporate name to "Statera BioPharma, Inc." and update its ticker symbol to "STAB" effective Wednesday, September 1, 2021. As part of the name change, Statera BioPharma (NASDAQ:STAB) plans to release a new company logo and launch a new company website at www.staterabiopharma.com. The new corporate name, Statera, taken from the Latin word for "balance," and tagline "Restoring Immune Health" was chosen to better reflect the company's strategic focus on a
1756dSEC
Cleveland BioLabs, Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
8-K - Cytocom, Inc. (0001318641) (Filer)
1757dPR
Cytocom, Inc. Second Quarter 2021 Financial Results Conference Call Replay Available Via Webcast
FORT COLLINS, Colo., Aug. 16, 2021 /PRNewswire/ -- Cytocom, Inc. (NASDAQ:CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the audio archive of the second quarter 2021 corporate and financial results conference call may be accessed from the "Investors" section of the Cytocom website at https://www.cytocom.com/investors/. The replay of the webcast will be archived on the website for 90 days beginning at approximately 10:00 a.m. ET, on August 16, 2021. About Cytocom Cytocom,
1757dSEC
SEC Form 10-Q filed by Cleveland BioLabs, Inc.
10-Q - Cytocom, Inc. (0001318641) (Filer)
1757dPR
Cytocom, Inc. Reports Second Quarter 2021 Financial Results
FORT COLLINS, Colo., Aug. 16, 2021 /PRNewswire/ -- Cytocom, Inc. (NASDAQ:CBLI), a leading biopharmaceutical company creating next-generation immune therapies for serious medical conditions that induce immune restoration and homeostasis, today reported recent corporate updates and financial results for the Company for the second quarter ended June 30, 2021, a period of time prior to the completion of the merger between legacy Cleveland BioLabs and the formerly private Cytocom Inc. Following the completion of the merger on July 27, 2021, Cytocom, Inc. emerged as a publicly traded entity.
1757dSEC
Cleveland BioLabs, Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - Cytocom, Inc. (0001318641) (Filer)
1761dPR
Cytocom, Inc. and La Jolla Institute for Immunology Announce Five-Year Research Alliance Agreement
FORT COLLINS, Colo., Aug. 12, 2021 /PRNewswire/ -- Cytocom, Inc. (NASDAQ:CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced a collaboration agreement to fund research and laboratory facilities at the La Jolla Institute for Immunology (LJI), a not-for-profit academic institution and a world leader in immunology research. The agreement is directed to research that will support the development of potential new immune-modulating agents targeting toll-like receptors for the treatment of cancer, infectious, autoimmune and chronic inflammatory diseases. The research will harness Cytocom's proprietary
1762dPR
Cytocom, Inc. Announces Participation at Liberty University's Empowering the Kingdom Through Business Conference
FORT COLLINS, Colo., Aug. 11, 2021 /PRNewswire/ -- Cytocom, Inc. (NASDAQ:CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the company will participate at the Empowering the Kingdom through Business Conference hosted by the Liberty University School of Business on August 10-12, 2021. Cytocom President and CEO, Mike K. Handley, will participate live as a featured panelist in the Healthcare Breakout session moderated by Dean Joseph Johnson on August 11, 2021. About Cytocom C
1763dPR
Cytocom, Inc. to Report Second Quarter 2021 Financial Results
FORT COLLINS, Colo., Aug. 10, 2021 /PRNewswire/ -- Cytocom, Inc. (NASDAQ:CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the Company will host a conference call and live audio webcast on Monday, August 16, 2021, at 8:30 a.m. ET, to discuss its corporate and financial results for the second quarter 2021. Conference Call & Audio Webcast Details Date Monday, August 16, 2021 Time 8:30 a.m. ET Telephone Access: U.S. and Canada 833-317-6003 Telephone Access: Inte
1764dSEC
Cleveland BioLabs, Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
8-K - Cytocom, Inc. (0001318641) (Filer)
1764dPR
Cytocom Inc. Provides Updates on Key Clinical Programs for Crohn's Disease, Hematology, Pancreatic Cancer and COVID-19
FORT COLLINS, Colo., Aug. 9, 2021 /PRNewswire/ -- Cytocom Inc. (NASDAQ:CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today provided an update regarding its portfolio of clinical programs. "We are excited and believe that we are well positioned to further the development of our clinical-stage pipeline and showcase the power of our expanded post-merger drug development capabilities," stated Michael K. Handley, President and CEO of Cytocom. "We are strategically focused on immune-modulating
1768dPR
Cytocom Inc. Provides Update on Completed Merger with Cleveland BioLabs
FORT COLLINS, Colo., Aug. 5, 2021 /PRNewswire/ -- Cytocom Inc. (NASDAQ:CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today provided shareholders with an update regarding its recent merger with Cleveland BioLabs. The all-stock transaction, first announced in October 2020, was formally completed on July 27, 2021. "With the Cleveland BioLabs merger completed and Cytocom now operating as a publicly-traded company, the management team at Cytocom is in the process of integrating both companies a
1769dINSIDER
SEC Form 3 filed by Handley Michael K
3 - Cytocom, Inc. (0001318641) (Issuer)
1769dINSIDER
SEC Form 4: Handley Michael K was granted 296,609 units of Common Stock
4 - Cytocom, Inc. (0001318641) (Issuer)
1774dSEC
Cleveland BioLabs, Inc. filed SEC Form 8-K: Financial Statements and Exhibits (Amendment)
8-K/A - Cytocom, Inc. (0001318641) (Filer)
1775dINSIDER
SEC Form 4: ARONSTAM PETER was granted 141,370 units of Common Stock
4 - Cytocom, Inc. (0001318641) (Issuer)
1775dINSIDER
SEC Form 4: McAvoy Cozette M. was granted 60,947 units of Common Stock
4 - Cytocom, Inc. (0001318641) (Issuer)

CBLI FAQ

5 questions

Where does CBLI stock trade?
Cleveland BioLabs, Inc. (CBLI) is listed on NASDAQ.
What sector and industry is CBLI in?
Cleveland BioLabs, Inc. operates in the Health Care sector, Biotechnology: Commercial Physical & Biological Resarch industry.
When did Cleveland BioLabs, Inc. go public?
Cleveland BioLabs, Inc. (CBLI) completed its IPO in 2006.
What companies are similar to CBLI?
Notable peers in the same industry include IQV (IQVIA Holdings Inc.), INCY (Incyte Corp.), PPD (PPD, Inc.), MEDP (Medpace Holdings Inc.), ICLR (ICON plc). Compare CBLI side-by-side with any of them on Quantisnow.
How can I track CBLI on Quantisnow?
Quantisnow aggregates Cleveland BioLabs, Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CBLI to receive live email and push alerts on every new disclosure.